#fp-001-42-mg

FP-001 42 mg Clinical Trial Completed

Foresee Pharmaceuticals completes Phase 3 trial for FP-001 42 mg for precocious puberty. FDA submission planned for 2026. CAMCEVI 21mg approved in Europe.